Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegilodecakin PK in healthy adults
NCT03267732Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2017
- Primary completion
- Oct 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ilodecakin in solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximal Serum Concentration, Time of Maximum Concentration and 2 more. Started Sep 2017; status: completed.
02
Drugs
ilodecakin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03267732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267732.